1.51  0.05 (3.42%)		08-25 16:00
Open: 1.46 High: 1.52 Volume: 437,267		Pre. Close: 1.46 Low: 1.42 Market Cap: 19(M)

Short term
Mid term
Targets	6-month :	1.81	1-year :	2.11
Resists	First :	1.54	Second :	1.81
Pivot price	1.34
Supports	First :	1.2	Second :	0.99
MAs	MA(5) :	1.47	MA(20) :	1.3
	MA(100) :	1.07	MA(250) :	0.95
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	84.5	D(3) :	85.8
RSI	RSI(14): 74.9
52-week	High :	1.54	Low :	0.55

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ BFRI ] has closed below upper band by 10.6%. Bollinger Bands are 51.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.52 - 1.53	1.53 - 1.54
Low:	1.4 - 1.41	1.41 - 1.42
Close:	1.49 - 1.51	1.51 - 1.52

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Sun, 23 Aug 2026
Biofrontera (BFRI) Quarterly Figures: Profit Per Share Clears Its Benchmark on the Day; Share Move: Shares Show Little Net Change in Latest Trading - Revenue Inflection Point - vinanet.vn

Thu, 13 Aug 2026
Biofrontera Inc. (BFRI) lifts revenue yet flags going concern and ITC impact - Stock Titan

Thu, 13 Aug 2026
Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Wed, 12 Aug 2026
Earnings To Watch: Biofrontera Inc (BFRI) Q2 2026 -- GF Value Sees 51% Downside - Yahoo Finance

Thu, 06 Aug 2026
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026 - The Manila Times

Wed, 05 Aug 2026
Biofrontera schedules Aug. 13 webcast for business update - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Shares Out	15 (M)
Shares Float	11 (M)
Held by Insiders	11.9 (%)
Held by Institutions	20.7 (%)
Shares Short	61 (K)
Shares Short P.Month	28 (K)

EPS	-0.44
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.41
Profit Margin	-13.8 %
Operating Margin	-4.4 %
Return on Assets (ttm)	-17.5 %
Return on Equity (ttm)	-988.4 %
Qtrly Rev. Growth	32.9 %
Gross Profit (p.s.)	2.46
Sales Per Share	3.1
EBITDA (p.s.)	-0.41
Qtrly Earnings Growth	0 %
Operating Cash Flow	-8 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	-3.52
PEG Ratio	0
Price to Book value	3.59
Price to Sales	0.48
Price to Cash Flow	-2.83

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.